Theranos has laid off most of its remaining workforce as it seeks to preserve cash and delay a bankruptcy filing for a few months, the Wall Street Journal reported Tuesday.
The layoffs reduced the Palo Alto, California-based blood-testing company’s staff from about 125 employees to fewer than two dozen workers, according to the report.
The company did not immediately return messages about the reported employee cuts.
The private company made Arizona its main testing grounds in 2013 when it began to roll out its unproven technology at Walgreens stores across metro Phoenix. The company opened 40 Theranos Wellness Centers in metro Phoenix and operated a laboratory at Arizona State University’s SkySong office complex in Scottsdale.
Theranos also successfully lobbied for a bill that allowed consumers to order any test without a doctor’s orders. Gov. Doug Ducey and legislative leaders joined Theranos founder and CEO Elizabeth Holmes for a bill-signing ceremony at Theranos’ Scottsdale lab.
But media reports and government regulators began to reveal problems with the company’s blood-testing technology.
Walgreens closed the 40 wellness centers and Theranos shut down its Scottsdale lab at SkySong.
Last month, the Securities and Exchange Commission said that Holmes and the company’s former President Ramesh “Sunny” Balwani conducted an “elaborate, years-long fraud” that deceived investors by claiming the company had developed a portable blood analyzer that could perform a range of tests from a small sample of blood.
By Ken Alltucker
Source: USA Today
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.